	Л		אדצ ר	17E0	55	FCUP	ITIF	S AN		ХСНА		ОММІ	SSION					
					Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See						d pursuant to Section 16(a) of the Securities Exchange Act of 1934								RSHIP OMB Number: 3235 Estimated average burden hours per response:				
1. Name and Address of Reporting Person* Megna Michael R					2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [KNSA]								(Check all applicable) Director			10% Ow		
(Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET				3. Date of Earliest Transaction (Month/Day/Year) 09/01/2022									CHIEF ACCOUNTING OFFICER					
(Street) HAMILTON D0 HM 11				_ 4.1	Line) X Form file Form file									ed by One Reporting Person ed by More than One Reporting			ı	
(S	tate)	(Zip)		-									Person					
	Tat	ole I - No	n-Deriv	vativ	ve Se	ecurities	s Acc	quired,	Dis	posed o	f, or Bei	neficial	y Owned					
Date						Execution Date, if any		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		d (A) or r. 3, 4 and	5) Securitie Beneficia Owned F	es Form ally (D) c following (I) (II		: Direct I r Indirect I str. 4) (	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Transact	ion(s)			Instr. 4)	
Class A Common Share 07/15				5/202	/2022			<b>A</b> <sup>(1)</sup>		703	A	\$9.50	6,	6,744		D		
Class A Common Share 09/02/				2/202	2022			М		775	A	(2)	7,:	7,519		D		
								F		228	D			291		D		
													Owned					
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	Date,	Code (Inst		n of		Expiration Date		e of Secu ar) Underly Derivati		ies g Security	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficia Owned Following Reported	e s illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)					Title	Amount or Number of Shares						
\$11.97	09/01/2022			A		31,460		(3)		08/31/2032	Class A Common Share	31,460	\$0	31,46	0	D		
(2)	09/01/2022			Α		15,730		(4)		(4)	Class A Common Share	15,730	\$0	15,73	0	D		
(2)	09/02/2022			М			775	(5)		(5)	Class A Common Share	775	\$0	2,323	3	D		
	this box if no lc n 16. Form 4 or itons may continitions may continitions may continitions may continition 1(b). Ind Address of Michael (Fi NIKSA PHA NDON HOU (S Security (Inst Common Sh Common Sh Common Sh Common Sh Common Sh Common Sh Common Sh Common Sh Conversion or Exercise Price of Derivative Security (2)	FORM 4         It his box if no longer subject to n 16. Form 4 or Form 5 tons may continue. See stion 1(b).         Ind Address of Reporting Person*         Michael R         If is the image of the image. The image of the	FORM 4       UNITER         It is box if no longer subject to n 16. Form 4 or Form 5 tons may continue. See tion 1(b).       STAT         Ind Address of Reporting Person*	FORM 4       UNITED STATEME         this box if no longer subject to n 16. Form 4 or Form 5 itons may continue. See iton 1(b).       STATEME         Ind Address of Reporting Person*       Fil         Ind Address of Reporting Person*       (Middle)         Ind Address of Reporting Person*       Interview         Ind Address of Reporting Person*       Interview         Ind Address of Reporting Person*       Interview         Interview       (First)       (Middle)         Interview       Interview       Interview         Interview       Interview	FORM 4       UNITED STATE         It is box if no longer subject to n 16. Form 4 or Form 5 itors may continue. See than 1(b).       STATEMENT         Filed puttors may continue. See than 1(b).       Filed puttors may continue. See than 1(b).       Ito puttors may continue. See than 1(b).         Ind Address of Reporting Person*       2.         Michael R       (Middle)         (First)       (Middle)         NIKSA PHARMACEUTICALS, LTD.       3.         NDON HOUSE 2 CHURCH STREET       4.         10N       D0       HM 11         (State)       (Zip)         Security (Instr. 3)         2. Transaction Date       09/02/202         Common Share       09/02/202         Conversion Price of Date for privative Security       3.         State of Date for portion Price of Date for portor Price of Date for portion Price of Date	FORM 4       UNITED STATES S         STATEMENT OF IN 16. Form 4 or Form 5 tions may continue. See         SIGE PURCING PERSON®         Michael R       2. Issue         (First)       (Middle)         NIKSA PHARMACEUTICALS, LTD. NDON HOUSE 2 CHURCH STREET       3. Date 09/01/2         ION       D0       HM 11         (State)       (Zip)         Table 1 - Non-Derivative State (Month/Day/Year)         Security (Instr. 3)       2. Transaction Date Price of Dorvarity         0       Jate point         2. Common Share       09/02/2022         State St	FORM 4         UNITED STATES SECUR         V           It is box if no longer subject to 16. Form 40 Form 5 bions may continue. See thion 1(9).         STATEMENT OF CHAIN           In 16. Form 40 Form 5 bions may continue. See thion 1(9).         Filed pursuant to Section 30(h).           Ind Address of Reporting Person*         2. Issuer Name and Kiniksa Phar           Michael R         2. Issuer Name and Kiniksa Phar           (First)         (Middle)           NIKSA PHARMACEUTICALS, LTD.         3. Date of Earliest 09/01/2022           ION         D0         HM 11           (State)         (Zip)           Table 1 - Non-Derivative Securities           Security (Instr. 3)           Date         09/02/2022           Common Share           09/02/2022         Common Share           Conversion or bare         09/02/2022           Common Share         09/02/2022           Common Share         09/02/2022           Conversion Date         3. Transaction Date or Earliest (A) or (A) or (B) or	FORM 4         UNITED STATES SECURITE Washin           STATEMENT OF CHANGE Storm may continue. See itom 1(b).           State of Form 5 of the or 5000 30(h) of the or 50000 30(h) of the ind Address of Reporting Person" Michael R	FORM 4       UNITED STATES SECURITES AN Washington, D.C.         STATEMENT OF CHANGES IN Consumption 10: 5 form 4 or form 5 bittem may continue. See its present to Section 16(a) of the Investme its ror section 30(n) of t	FORM 4       UNITED STATES SECURITES AND E         Washington, D.C. 2005       STATEMENT OF CHANGES IN BEIT         In the box if no longer subject to not form 4 or form 5 section 3(6) of the lowestment Constrained on the form 4 or form 5 section 3(16) of the lowestment Constrained on the form 4 or form 5 section 3(16) of the lowestment Constrained on t	FORM 4       UNITED STATES SECURITIES AND EXCHA Washington, D.C. 2054         This box if no longer subject to its form 4 or Form 5 gibtor 1(6).       STATEMENT OF CHANGES IN BENEFICI Network and Ticker or Trading Symbol Kiniksa Pharmaccuticals, Ltd. [KN         Michael R (First)       2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaccuticals, Ltd. [KN         Michael R (First)       3. Date of Earliest Transaction (Month/Day/Year) (9/01/2022         Tobo HOUSE 2 CHURCH STREET (State)       3. Date of Carliest Transaction (Month/Day/Year) (9/01/2022       3. Date of Carliest Transaction (Month/Day/Year) (9/01/2022         Table 1 - Non-Derivative Securities Acquired, Disposed of Month/Day/Year)       3. Transaction Date (Month/Day/Year)       3. Transaction (Month/Day/Year)       3. Security (Month/Day/Year)       4. Securitiest (Month/Day/Year)       4. Securitiest (Month/Da	Source of the longer subject to the form a or parts of the form a or part of the form a or parts of the form a or parts of the form a or parts of the form a or part of the for	FORM 4         DISTRUCTION CONTROL OF CHANGES IN DENEFFICIAL OWNERS           STATEMENT OF CHANGES IN DENEFFICIAL OWNERS           Total controls of the securities Exchange Act of 1921 or dection 30(n) of the Securities Exchange Act of 1921 or dection 30(n) of the Securities Exchange Act of 1921 or dection 30(n) of the Securities Exchange Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1921 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investment Company Act of 1920 or dection 30(n) of the Investmen	Prom 4         Initial provide a subject to the form of orgen subject to the for orgen subject to the form of orgen subject to t	Prome 4         DINTED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2049           Statement of longer subject to store (v).         STATEMENT OF CHANGES IN BENEFICIAL OWNERSION Sectore 30(7) of the investment Company Act of 1930           Address of Reporting Person*         Ling unsame to sectore 10(0) of the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930           Michael R         Ling unsame to sectore 10(0) of the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930           Michael R         Ling and Takes Pharmaceuticals, Ltd. [KNSA]         Statestore 10(0) of the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930           Michael R         Ling and the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930           Michael R         Ling and the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930           Michael R         Ling and the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930         Statestore 10(0) of the investment Company Act of 1930           Michael R         Ling and the investment Company Act of 1930         Ling and the investment Company Act of 1930         Ling and the investment Company Act of 1930	Prom 4         UNITED STATES SECURITES AND EXCHANGE OWNERSION Waitington. D.C. 20349         Data Data Data Data Data Data Data Data	Prom 4         UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20349         OMB APPRO           The output on output statistic in the output on output statistic int the o	

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2022 to July 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

2. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.

4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

5. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

<u>/s/ Madelyn Zeylikman,</u> <u>Attorney-in-Fact</u>

09/06/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.